Ibrutinib not checked

Johnson & Johnson (Janssen) · JNJ-54179060 · PCI-32765

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
21 active
26 in total · 25 in the EU
Targets
—
None known yet

What this is

How it works
Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.BTK inhibitor Named by hand
How it’s given
“Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.”In the company’s words, NCT03462719 on ClinicalTrials.gov
Tested for
Leukemia, Lymphocytic, Chronic, B-Cell (3 trials), Small Lymphocytic Lymphoma (2 trials), Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease and 6 more
Main trialPhase 3
“The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).”In the company’s words, NCT03462719 on ClinicalTrials.gov
Other names
JNJ-54179060 · PCI-32765

Other drugs for Leukemia, Lymphocytic, Chronic, B-Cell

All 64 drugs for Leukemia, Lymphocytic, Chronic, B-Cell

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials26

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 26 Feb 2021 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 3Active, not recruiting 31 Dec 2026 A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 2Active, not recruiting 15 Dec 2027 A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Phase 1Enrolling by invitation 19 Jan 2028 A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 3Completed 30 May 2022 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Phase 3Authorised not given A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Phase 2Authorised not given Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia - A MULTICENTER OPEN LABEL, SINGLE ARM EUROPEAN PHASE II STUDY (ECWM-2)
Phase 2Authorised not given Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
Phase 2Authorised not given Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
Phase 2Authorised not given HOVON 158 CLL: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)
Phase 2Expired not given A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy
Phase 2Authorised not given MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
Phase 2Authorised not given Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis. CLL2323
Phase 2Ended not given HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
Phase 3Ended not given TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial
Phase 2Authorised not given Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)
Phase 2Authorised not given Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)
Phase 2Authorised not given Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.
Phase 1/2Authorised not given OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
Phase 2/3Authorised not given ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma
Phase 2Authorised not given Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line
Phase 2Authorised not given Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL
Phase 1/2Ended not given A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs)
Phase 2Authorised not given EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations
Phase 4Authorised not given A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
Phase 2Authorised not given HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ibrutinib

Following is part of Solo: you see every change to Ibrutinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in